Amanote Research
Register
Sign In
Immune-Checkpoint Blockade Aptamers as a Feasible Clinical Alternative to Monoclonal Antibodies
Cancer Cell & Microenvironment
doi 10.14800/ccm.1247
Full Text
Open PDF
Abstract
Available in
full text
Date
March 30, 2016
Authors
Unknown
Publisher
Smart Science and Technology, LLC
Related search
Masterful Antibodies: Checkpoint Blockade
Cancer immunology research
Cancer Research
Immunology
Immune Checkpoint Blockade in Lymphoid Malignancies
FEBS Journal
Biochemistry
Cell Biology
Molecular Biology
Systemic Immunological Biomarkers of Clinical Responses in Immune Checkpoint Blockade Therapies
Lung Cancer Management
Immune Checkpoint Blockade for Hematologic Malignancies: A Review
Stem Cell Investigation
The FG Loop of PD-1 Serves as a ‘Hot-Spot’ for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
iScience
Multidisciplinary
Immune Checkpoint Blockade: Subjugation of the Masses
Inhibition of QPCTL Induces Myeloid Immune Checkpoint Blockade
Cancer Discovery
Oncology
Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade
Hepatology
Medicine
Hepatology
Monoclonal Antibodies: A Tool in Clinical Research
Indian Journal of Clinical Medicine